← ANALYST RATINGS · TIPRANKS
Aktis Oncology, Inc. (AKTS): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $36.25, the highest $40.00, the lowest $33.00. The average is +140.7% from the last price of $15.06.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $15.00 → $14.00−6.7% | Sell | −7.0% | Downgrade | 17.10.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $15.00 → $14.50−3.3% | Sell | −3.7% | Downgrade | 17.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $15.50 → $14.50−6.5% | Hold | −3.7% | Reiterated | 17.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $15.00 → $14.50−3.3% | Sell | −3.7% | Downgrade | 17.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $15.00 → $14.00−6.7% | Sell | −7.0% | Downgrade | 17.10.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $15.50 → $14.50−6.5% | Hold | −3.7% | Reiterated | 17.10.26on TipRanks 19:05 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $35.00 | Buy | +132.4% | Reiterated | 02.10.26on TipRanks Oct 5 04:07 | −0.7%next day −0.7% · 5 days −3.2% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $40.00 | Buy | +165.6% | Initiated | 09.09.26on TipRanks 06:20 | −3.4%next day +0.1% · 5 days −4.5% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $37.00 | Buy | +145.7% | Initiated | 18.08.26on TipRanks Aug 19 07:07 | +1.8%next day −0.1% · 5 days +7.0% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $34.00 | Buy | +125.8% | Reiterated | 14.08.26on TipRanks 07:10 | +5.0%next day −0.4% · 5 days −2.1% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $33.00 | Buy | +119.1% | Assigned | 14.08.26on TipRanks 07:10 | +5.0%next day −0.4% · 5 days −2.1% | ↗ |
| Alexandra Ramsey★★★★★★★★★★#6281 · hits 75% · avg +21.3% | William Blair | — | Buy | — | Reiterated | 14.08.26on TipRanks 04:05 | +5.0%next day −0.4% · 5 days −2.1% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $40.00 | Buy | +165.6% | Initiated | 16.06.26on TipRanks Jun 15 16:15 | +10.0%next day +5.2% · 5 days +28.8% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $35.00 | Buy | +132.4% | Assigned | 03.06.26on TipRanks Jun 2 11:50 | +3.9%next day −3.7% · 5 days −3.4% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 11.05.26on TipRanks 17:45 | +8.1%next day −1.6% · 5 days −5.6% | ↗ |
| Jonathan Chang★★★★★★★★★★#2398 · hits 37% · avg +7.3% | Leerink Partners | $31.00 | Buy | +105.8% | Initiated | 03.02.26on TipRanks 06:35 | −4.1%next day −4.2% · 5 days −15.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Aktis Oncology, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.80 at a price of $19.47 (+83.9%); now: $35.80 at $15.06 (+137.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 2 |
| Buy | 3 | 2 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Aktis Oncology, Inc.
- CEO: Matthew Roden
- Employees: 79
- 17 Drydock Avenue, Boston, MA, 02210, US
- www.aktisoncology.com
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 101 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗